Parp1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PARP1 (Poly(ADP-ribose) Polymerase 1) is a nuclear enzyme that catalyzes the transfer of ADP-ribose units from NAD+ to target proteins, forming poly(ADP-ribose) polymers. This post-translational modification plays critical roles in DNA repair, genomic stability, cell death pathways, and neuroinflammation. PARP1 is increasingly recognized as a key player in neurodegenerative diseases, where excessive activation leads to parthanatos—a form of programmed cell death distinct from apoptosis.
PARP1 functions as a DNA damage sensor and repair enzyme. Upon detection of DNA strand breaks, PARP1 binds to damaged DNA and undergoes autopoly(ADP-ribos)ylation, which recruits DNA repair proteins to the site of injury. The enzyme participates in base excision repair (BER) and single-strand break repair (SSBR) pathways.
Key functions include:
PARP1 overactivation contributes to dopaminergic neuron death in PD. Oxidative stress and mitochondrial dysfunction lead to DNA damage that excessively activates PARP1. Studies show elevated PARP activity in PD postmortem brain tissue. PARP inhibitors (e.g., PJ-34, DPQ) demonstrate neuroprotection in MPTP and 6-OHDA models.
PARP1-mediated cell death (parthanatos) is implicated in motor neuron degeneration. TDP-43 proteinopathy intersects with PARP1 pathways. C9orf72 hexanucleotide repeats may increase DNA damage stress. PARP inhibitors show promise in SOD1 and TDP-43 mouse models.
PARP1 overactivation after ischemic stroke leads to extensive neuronal death through NAD+ depletion. PARP inhibitors administered post-stroke reduce infarct size and improve functional outcomes in preclinical models.
PARP1 involvement in AD includes:
PARP1 is expressed throughout the brain with highest expression in:
Expression is upregulated by oxidative stress, DNA-damaging agents, and neuroinflammation.
| Agent | Mechanism | Development Stage | Notes |
|---|---|---|---|
| PJ-34 | PARP1/2 inhibitor | Preclinical | Neuroprotective in PD models |
| DPQ | PARP1 inhibitor | Preclinical | Reduces 6-OHDA toxicity |
| Olaparib | PARP1/2/3 inhibitor | Clinical (oncology) | Repurposing potential |
| Niraparib | PARP1/2 inhibitor | Clinical (oncology) | Brain penetration being evaluated |
| Rucaparib | PARP inhibitor | Clinical (oncology) | Phase I/II for neurodegeneration planned |
The study of Parp1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.